ARROVEN - brentuximab vedotin PASS, version 1.1 dated on 14 June 2012

• Research type

  Research Study

• Full title

  Post-Authorisation Safety Study (PASS) MA25101: An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

• IRAS ID

  121193

• Contact name

  Kim Linton

• Contact email

  kim.linton@manchester.ac.uk

• Sponsor organisation

  Millennium Pharmaceuticals, Inc.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  13/NW/0208

• Date of REC Opinion

  24 Apr 2013

• REC opinion

  Further Information Favourable Opinion